(VIANEWS) – Provident Financial Services (PFS), Zynex (ZYXI), Regency Centers Corporation (REG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Provident Financial Services (PFS)
52.2% sales growth and 7.19% return on equity
Provident Financial Services, Inc. operates as the bank holding company for Provident Bank that provides various banking products and services to individuals, families, and businesses in the United States. Its deposit products include savings, checking, interest-bearing checking, money market deposit, and certificate of deposit accounts, as well as IRA products. The company's loan portfolio comprises commercial real estate loans that are secured by properties, such as multi-family apartment buildings, office buildings, and retail and industrial properties; commercial business loans; fixed-rate and adjustable-rate mortgage loans collateralized by one- to four-family residential real estate properties; commercial construction loans; and consumer loans consisting of home equity loans, home equity lines of credit, marine loans, personal loans and unsecured lines of credit, and auto and recreational vehicle loans. It also offers cash management, remote deposit capture, payroll origination, escrow account management, and online and mobile banking services; and business credit cards. In addition, the company provides wealth management services comprising investment management, trust and estate administration, financial planning, tax compliance and planning, and private banking. Further, it sells insurance and investment products, including annuities; operates as a real estate investment trust for acquiring mortgage loans and other real estate related assets; and manages and sells real estate properties acquired through foreclosure. The company was founded in 1839 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Provident Financial Services has a trailing twelve months EPS of $1.6.
PE Ratio
Provident Financial Services has a trailing twelve months price to earnings ratio of 8.98. Meaning, the purchaser of the share is investing $8.98 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.19%.
Yearly Top and Bottom Value
Provident Financial Services’s stock is valued at $14.37 at 20:22 EST, way under its 52-week high of $19.62 and higher than its 52-week low of $13.21.
Volume
Today’s last reported volume for Provident Financial Services is 250874 which is 77.84% below its average volume of 1132370.
Moving Average
Provident Financial Services’s value is under its 50-day moving average of $14.92 and under its 200-day moving average of $15.67.
2. Zynex (ZYXI)
20.7% sales growth and 16.75% return on equity
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, Zynex has a trailing twelve months EPS of $0.23.
PE Ratio
Zynex has a trailing twelve months price to earnings ratio of 45.74. Meaning, the purchaser of the share is investing $45.74 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.75%.
3. Regency Centers Corporation (REG)
7.7% sales growth and 5.78% return on equity
Regency Centers is the preeminent national owner, operator, and developer of shopping centers located in affluent and densely populated trade areas. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member.
Earnings Per Share
As for profitability, Regency Centers Corporation has a trailing twelve months EPS of $2.05.
PE Ratio
Regency Centers Corporation has a trailing twelve months price to earnings ratio of 28.92. Meaning, the purchaser of the share is investing $28.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.78%.
Yearly Top and Bottom Value
Regency Centers Corporation’s stock is valued at $59.29 at 20:22 EST, way below its 52-week high of $68.47 and higher than its 52-week low of $55.65.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.9%, now sitting on 1.42B for the twelve trailing months.
Sales Growth
Regency Centers Corporation’s sales growth for the next quarter is 7.7%.
4. Tetra Tech (TTEK)
7.6% sales growth and 18.05% return on equity
Tetra Tech, Inc. provides consulting and engineering services worldwide. The company operates through Government Services Group (GSG) and Commercial/International Services Group (CIG) segments. The GSG segment offers early data collection and monitoring, data analysis and information technology, science and engineering applied research, engineering design, construction management, and operations and maintenance services; and climate change and energy management consulting, as well as greenhouse gas inventory assessment, certification, reduction, and management services. This segment serves federal, state, and local governments, and development agencies in water resources analysis and water management, environmental monitoring, data analytics, government consulting, waste management, and a range of civil infrastructure master planning and engineering design markets. The CIG segment provides early data collection and monitoring, data analysis and information management, feasibility studies and assessments, science and engineering applied research, engineering design, construction management, and operations and maintenance services. This segment serves natural resources, energy, and utilities markets, as well as civil infrastructure master planning and engineering design markets. Tetra Tech, Inc. was founded in 1966 and is headquartered in Pasadena, California.
Earnings Per Share
As for profitability, Tetra Tech has a trailing twelve months EPS of $4.94.
PE Ratio
Tetra Tech has a trailing twelve months price to earnings ratio of 41.45. Meaning, the purchaser of the share is investing $41.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.6%, now sitting on 4.11B for the twelve trailing months.
Moving Average
Tetra Tech’s worth is higher than its 50-day moving average of $200.89 and way above its 200-day moving average of $173.29.
5. Kamada Ltd. (KMDA)
6.8% sales growth and 5.9% return on equity
Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.
Earnings Per Share
As for profitability, Kamada Ltd. has a trailing twelve months EPS of $0.23.
PE Ratio
Kamada Ltd. has a trailing twelve months price to earnings ratio of 23.3. Meaning, the purchaser of the share is investing $23.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 22.9%, now sitting on 149.54M for the twelve trailing months.
Volume
Today’s last reported volume for Kamada Ltd. is 30819 which is 39.19% above its average volume of 22141.
Yearly Top and Bottom Value
Kamada Ltd.’s stock is valued at $5.36 at 20:22 EST, way below its 52-week high of $6.53 and way above its 52-week low of $4.08.
6. ResMed (RMD)
6.4% sales growth and 22.39% return on equity
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, ResMed has a trailing twelve months EPS of $6.05.
PE Ratio
ResMed has a trailing twelve months price to earnings ratio of 30.72. Meaning, the purchaser of the share is investing $30.72 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.39%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.2%, now sitting on 4.58B for the twelve trailing months.
Previous days news about ResMed(RMD)
- According to Zacks on Thursday, 6 June, "Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) . "
- According to Zacks on Friday, 7 June, "Some other top-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) , sporting a Zacks Rank #1 (Strong Buy) each. "
- According to Zacks on Friday, 7 June, "Some better-ranked stocks in the broader medical space are Hims & Hers Health (HIMS Quick QuoteHIMS – Free Report) , Medpace (MEDP Quick QuoteMEDP – Free Report) and ResMed (RMD Quick QuoteRMD – Free Report) , presently sporting a Zacks Rank #1 (Strong Buy) each. "
